Cervical cancer (CC) is the third leading cause of death in women in Montenegro. Human papillomavirus (HPV) is the causative agent of CC however, HPV genotype distribution varies across regions. This study examined the distribution and impact of vaccine-related high-risk (HR)-HPVs on the development of cervical dysplasia in Montenegrin women. A total of 187 women who had a clinical indication for cervical biopsy were enrolled. Based on histopathological findings, women were classified into 2 groups, with and without dysplasia. HR-HPV was detected by real-time PCR. Twelve HR-HPV genotypes were detected in 40.6% of cervical samples. The 7 most prevalent HR-HPVs in order of decreasing frequency were HPV 16 (39.5%), 45 (23.7%), 31 (21.0%), 33 (17.1%), 18 (6.6%), 52 (6.6%), and 58 (6.6%), all of them are targeted by nonavalent vaccine. Vaccine-related HR-HPVs had a higher prevalence (92.1%) than the other HR-HPVs detected in HR-HPV–positive samples. Among HR-HPV–positive women, HPV 16 and 33 were more common in women with dysplasia than in those without dysplasia (HPV 16: 28.9 vs 7.2%; HPV 33: 11.8 vs 3.6%). HPV 16 was the most common HR-HPV genotype in cervical samples, followed by HPV 45, 31, 33, 18, 52, and 58. HPV 16 and 33 were shown to be associated with the development of cervical dysplasia. These results indicate that prophylactic nonavalent vaccine can potentially prevent approximately 90% of HR-HPV infections and 60% of cervical dysplasia cases in Montenegrin women.
Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424.
Shwe M-M , Harano T , Okada S , Win A-A , Aye K-S , Thu H-M , et al. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama 2014; 68(2): 79–87. https://doi.org/10.18926/AMO/52404. PMID: 24743783.
Poljak M , Seme K , Maver PJ , Kocjan BJ , Cuschieri KS , Rogovskaya SI , et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2013 Dec 31; 31(Suppl 7): H59–70. https://doi.org/10.1016/j.vaccine.2013.03.029. PMID: 24332298.
Malignant neoplasms in Montenegro 2013. Podgorica: insitute of public health of Montenegro, center for control and prevention of non-communicable diseases, Registry of malignant neoplasms of Montenegro, 2018.
Ferlay J , Ervik M , Lam F , Colombet M , Mery L , Piñeros M , et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/today, accessed [08.06.2021].
Medeiros LR , Hilgert JB , Zanini RR , Berwanger O , Bozzetti MC , Mylius LC , et al. Vertical transmition of human papilloma virus: a systematic quantitive review. Cad Saude Publica 2005; 21(4): 1006–15.
ZurHausen H. Papillomaviruses in the causation of human cancers e a brief historical account. Virology 2009; 384: 260e5. http://doi.org/10.1016/j.virol.2008.11.046.
Lorenzi AT , Syrj€anen KJ , Longatto-filho A. Human papillomavirus (HPV) screening and cervical cancer burden. A Braz Perspect Virol J 2015; 1e6. http://doi.org/10.1186/s12985-015-0342-0.
ZurHausen H . Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55e78.
Muñoz N , Bosch FX , de Sanjosé S , Herrero R , Castellsagué X , Shah KS , et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27. https://doi.org/10.1056/nejmoa021641.
Luostarinen T , Apter D , Dillner J , Eriksson T , Harjula K , Natunen K , et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer 2018; 142: 2186–7. https://doi.org/10.1002/ijc.31231.
Kim KS , Park S , Ko K-N , Yi S , Cho YJ . Current status of human papillomavirus vaccines. Clin Exp Vaccin Res 2014; 3(2): 168–75.
Pils S , Joura E . From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015; 21(9): 827–33.
Krul EJ , Van De Vijver MJ , Schuuring E , Van Kanten RW , Peters AA , Fleuren GJ . Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to The Netherlands, a low-risk country. Int J Gynecol Cancer 1999; 9(3): 206–11.
Vinodhini K , Shanmughapriya S , Das BC , Natarajaseenivasan K . Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstetr 2012; 285: 771–7. https://doi.org/10.1007/s00404-011-2155-8.
Kovachev S , Slavov V , Slavova K . Prevalence of human papillomavirus infection in women in some cities and regions of Bulgaria. J Med Virol 2013; 85(9): 1577–84. https://doi.org/10.1002/jmv.23652.
Moga MA , Irimie M , Oanta A , Pascu A , Burtea V . Type-specific prevalence of human papillomavirus by cytology in Romania. Asian Pac J Cancer Prev 2014; 15(16): 6887–92. http://doi.org/10.7314/APJCP.2014.15.16.6887.
Tasic D , Lazarevic I , Knezevic A , Tasic L , Pikula A , Perisic Z , et al. The impact of environmental and behavioural cofactors on the development of cervical disorders in HR-HPV-infected women in Serbia. Epidemiol Infect 2018 Oct; 146(13): 1714–23. https://doi.org/10.1017/S0950268818001668. Epub 2018 Jun 20. PMID: 29923470.
Zejnullahu Raçi P , Hošnjak L , Poljak M , Lepej SŽ , Vince A . Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics. Ginekol Pol 2018; 89(9): 485–94. https://doi.org/10.5603/GP.a2018.0083. PMID: 30318575.
de Sanjosé S , Diaz M , Castellsagué X , Clifford G , Bruni L , Muñoz N , et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007 Jul; 7(7): 453–9. https://doi.org/10.1016/S1473-3099(07)70158-5. PMID: 17597569.
Wagner M , Bennetts L , Patel H , Welner S , de Sanjose S , Weiss TW . Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent Cancer 2015 Apr 28; 10: 13. https://doi.org/10.1186/s13027-015-0008-y. PMID: 25987893; PMCID: PMC4435914.
Salimović-Bešić I , Hukić M . Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears. Epidemiol Infect 2015 Sep; 143(12): 2604–12. https://doi.org/10.1017/S0950268814003720. Epub 2015 Jan 12. PMID: 25578155.
Vujosević D , Vuksanović V , Poljak M , Jokmanović N . Human papillomavirus genotype spectrum in studied group of Montenegrin women. Acta Med (Hradec Kralove). 2012; 55(3): 130–2. https://doi.org/10.14712/18059694.2015.50. PMID: 23297521.
Dabeski D , Dabeski A , Antovska V , Trajanova M , Todorovska I , Sima A . Human papillomavirus infections in women with and without squamous cell abnormalities of the uterine cervix. Scripta Med 2019; 50(2): 69–76.
Filipi K , Tedeschini A , Paolini F , Celicu S , Morici S , Kota M , et al. Genital human papillomavirus infection and genotype prevalence among Albanian women: a cross-sectional study. J Med Virol 2010 Jul; 82(7): 1192–6. https://doi.org/10.1002/jmv.21803. PMID: 20513083.
De Vuyst H , Clifford G , Li N , Franceschi S . HPV infection in Europe. Eur J Cancer 2009 Oct; 45(15): 2632–9. https://doi.org/10.1016/j.ejca.2009.07.019. Epub 2009 Aug 24. PMID: 19709878.
Sabol I , Milutin Gašperov N , Matovina M , Božinović K , Grubišić G , Fistonić I , et al. Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia. PLoS One 2017 Jul 10; 12(7): e0180480. https://doi.org/10.1371/journal.pone.0180480. PMID: 28692681; PMCID: PMC5503252.
Arbyn M , Benoy I , Simoens C , Bogers J , Beutels P , Depuydt C . Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Preven: A Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2009 Jan; 18(1): 321–30. https://doi.org/10.1158/1055-9965.epi-08-0510. PMID: 19124515.
Clifford GM , Smith JS , Aguado T , Franceschi S . Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003 Jul 7; 89(1): 101–5. https://doi.org/10.1038/sj.bjc.6601024. PMID: 12838308; PMCID: PMC2394204.
Karadža M , Židovec Lepej S , Planinić A , Grgić I , Ćorušić A , Planinić P , et al. Distribution of human papillomavirus genotypes in women with high-grade cervical intraepithelial lesions and cervical carcinoma and analysis of human papillomavirus-16 genomic variants. Croat Med J 2021 Feb 28; 62(1): 68–79. https://doi.org/10.3325/cmj.2021.62.68. PMID: 33660963; PMCID: PMC7976879.
Forslund O , Antonsson A , Edlund K , van den Brule AJ , Hansson BG , Meijer CJ , et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002 Apr; 66(4): 535–41. https://doi.org/10.1002/jmv.2178. Erratum in: J Med Virol 2002 Jul; 67(3): 467. PMID: 11857534.
Pista A , Oliveira A , Verdasca N , Ribeiro F . Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect 2011 Jun; 17(6): 941–6. https://doi.org/10.1111/j.1469-0691.2010.03387.x. Epub 2010 Dec 3. PMID: 21040156.
Cuschieri KS , Cubie HA , Whitley MW , Seagar AL , Arends MJ , Moore C , et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004 Jan; 57(1): 68–72. https://doi.org/10.1136/jcp.57.1.68. PMID: 14693839; PMCID: PMC1770158.
Balbi G , Napolitano A , Giordano F , Capuano S , Manganaro MA , Di Martino L , et al. Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions. Eur J Gynaecol Oncol 2012; 33(5): 467–71. PMID: 23185789.
Liu Y , Ang Q , Wu H , Xu J , Chen D , Zhao H , et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China’s top 3 hospital, 2009-2019. Virol J 2020 Jul 13; 17(1): 104. https://doi.org/10.1186/s12985-020-01383-1. PMID: 32660490; PMCID: PMC7359485.
Bulkmans NW , Berkhof J , Bulk S , Bleeker MC , Van Kemenade FJ , Rozendaal L , et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419Y1424.